← All trials
NCT04511819
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2020
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2020
- First posted
- Aug 13, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 410
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fulcrum TherapeuticsLead sponsor
- Fulcrum TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.